{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Granulocyte-Macrophage+Stimulating+Factor+%28GM-CSF%29",
    "query": {
      "intervention": "Granulocyte-Macrophage Stimulating Factor (GM-CSF)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 286,
    "total_pages": 29,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Granulocyte-Macrophage+Stimulating+Factor+%28GM-CSF%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-01T14:36:02.876Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00206700",
      "title": "Open-label Trial of Leukine in Active Crohn's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Crohn Disease"
      ],
      "interventions": [
        {
          "name": "Sargramostim (Leukine)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 378,
      "start_date": "2003-02",
      "completion_date": "2006-12",
      "has_results": false,
      "last_update_posted_date": "2013-12-04",
      "last_synced_at": "2026-10-01T14:36:02.876Z",
      "location_count": 98,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Berkeley, California + 80 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00206700"
    },
    {
      "nct_id": "NCT01338012",
      "title": "Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "sipuleucel-T",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Dendreon",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 8,
      "start_date": "2011-12",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2017-06-05",
      "last_synced_at": "2026-10-01T14:36:02.876Z",
      "location_count": 4,
      "location_summary": "Laguna Hills, California • Portland, Oregon • Seattle, Washington",
      "locations": [
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01338012"
    },
    {
      "nct_id": "NCT01183897",
      "title": "3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Months and older"
      },
      "enrollment_count": 31,
      "start_date": "2010-08-12",
      "completion_date": "2018-09-25",
      "has_results": true,
      "last_update_posted_date": "2019-08-13",
      "last_synced_at": "2026-10-01T14:36:02.876Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01183897"
    },
    {
      "nct_id": "NCT00462605",
      "title": "MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Acute Lymphoblastic Leukemia in Remission",
        "Adult Acute Megakaryoblastic Leukemia (M7)",
        "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)",
        "Adult Acute Monoblastic Leukemia (M5a)",
        "Adult Acute Monocytic Leukemia (M5b)",
        "Adult Acute Myeloblastic Leukemia With Maturation (M2)",
        "Adult Acute Myeloblastic Leukemia Without Maturation (M1)",
        "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities",
        "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)",
        "Adult Acute Myelomonocytic Leukemia (M4)",
        "Adult Erythroleukemia (M6a)",
        "Adult Pure Erythroid Leukemia (M6b)",
        "Chronic Myelomonocytic Leukemia",
        "de Novo Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable",
        "Previously Treated Myelodysplastic Syndromes",
        "Recurrent Adult Acute Lymphoblastic Leukemia",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Refractory Anemia",
        "Refractory Anemia With Excess Blasts",
        "Refractory Anemia With Ringed Sideroblasts",
        "Refractory Cytopenia With Multilineage Dysplasia",
        "Secondary Acute Myeloid Leukemia",
        "Secondary Myelodysplastic Syndromes",
        "Untreated Adult Acute Lymphoblastic Leukemia",
        "Untreated Adult Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "entinostat",
          "type": "DRUG"
        },
        {
          "name": "sargramostim",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2007-04",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2017-07-18",
      "last_synced_at": "2026-10-01T14:36:02.876Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00462605"
    },
    {
      "nct_id": "NCT00001239",
      "title": "Combination Chemotherapy (FLAC) Combined With Granulocyte-Macrophage Colony Stimulating Factor in Locally Advanced and Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "FLAC with GM-CSF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 100,
      "start_date": "1989-07",
      "completion_date": "2001-01",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-10-01T14:36:02.876Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001239"
    },
    {
      "nct_id": "NCT00415857",
      "title": "Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Peptide Vaccine (PR1 Peptide)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Peginterferon alfa-2b",
          "type": "DRUG"
        },
        {
          "name": "Imatinib",
          "type": "DRUG"
        },
        {
          "name": "GM-CSF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2006-12",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2018-08-21",
      "last_synced_at": "2026-10-01T14:36:02.876Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00415857"
    },
    {
      "nct_id": "NCT01266083",
      "title": "WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Galinpepimut-S",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GM-CSF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Montanide",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Sellas Life Sciences Group",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2011-01-14",
      "completion_date": "2016-09-30",
      "has_results": true,
      "last_update_posted_date": "2024-11-19",
      "last_synced_at": "2026-10-01T14:36:02.876Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01266083"
    },
    {
      "nct_id": "NCT02799472",
      "title": "Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Arthritis, Rheumatoid"
      ],
      "interventions": [
        {
          "name": "GSK3196165",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "MTX",
          "type": "DRUG"
        },
        {
          "name": "Folic (or folinic) acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2016-06-15",
      "completion_date": "2017-10-30",
      "has_results": true,
      "last_update_posted_date": "2021-01-11",
      "last_synced_at": "2026-10-01T14:36:02.876Z",
      "location_count": 8,
      "location_summary": "El Cajon, California • Fort Lauderdale, Florida • Miami, Florida + 5 more",
      "locations": [
        {
          "city": "El Cajon",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Pinellas Park",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02799472"
    },
    {
      "nct_id": "NCT02873819",
      "title": "Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of the Oral Cavity"
      ],
      "interventions": [
        {
          "name": "GL-0817",
          "type": "DRUG"
        },
        {
          "name": "Hiltonol",
          "type": "DRUG"
        },
        {
          "name": "Sargramostim",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gliknik Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2017-03-30",
      "completion_date": "2021-05-25",
      "has_results": false,
      "last_update_posted_date": "2022-03-08",
      "last_synced_at": "2026-10-01T14:36:02.876Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02873819"
    },
    {
      "nct_id": "NCT00323557",
      "title": "Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Sargramostim (GM-CSF)",
          "type": "DRUG"
        },
        {
          "name": "Pneumococcal Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 39,
      "start_date": "2004-06",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2012-12-05",
      "last_synced_at": "2026-10-01T14:36:02.876Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00323557"
    }
  ]
}